BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, January 16, 2026
Home » Authors » Kim Coghill

Articles by Kim Coghill

House, Senate Pass Bioterrorism Bill On To Bush For Signature

May 28, 2002
By Kim Coghill

FDA Panel Votes In Favor Of Biogen's Amevive For Psoriasis

May 24, 2002
By Kim Coghill
SILVER SPRING, Md. - A panel of experts advising the FDA recommended approval of Biogen Inc.'s psoriasis drug Amevive on Thursday. (BioWorld Today)
Read More

FDA Panel Votes In Favor Of Biogen's Amevive For Psoriasis

May 24, 2002
By Kim Coghill
SILVER SPRING, Md. - A panel of experts advising the FDA recommended approval of Biogen Inc.'s psoriasis drug Amevive on Thursday. (BioWorld Today)
Read More

BIO Holds First Meeting On Biotechnology And The Law

May 22, 2002
By Kim Coghill

BIO Holds First Meeting On Biotechnology And The Law

May 22, 2002
By Kim Coghill

PDL Drops Development Of Zamyl After Phase III Failure

May 21, 2002
By Kim Coghill
Protein Design Labs Inc. decided against further development of Zamyl as an acute myeloid leukemia treatment on news that its Phase III trial failed to show statistical significance. (BioWorld Today)
Read More

PDL Drops Development Of Zamyl After Phase III Failure

May 21, 2002
By Kim Coghill
Protein Design Labs Inc. decided against further development of Zamyl as an acute myeloid leukemia treatment on news that its Phase III trial failed to show statistical significance. (BioWorld Today)
Read More

Variagenics Trims Staff, Programs To Focus On Cancer Diagnostics

May 20, 2002
By Kim Coghill

Variagenics Trims Staff, Programs To Focus On Cancer Diagnostics

May 20, 2002
By Kim Coghill

Manufacturing Snag Could Set NPS Back On Osteoporosis Drug

May 17, 2002
By Kim Coghill
Previous 1 2 … 119 120 121 122 123 124 125 126 127 … 142 143 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 16, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 16, 2026.
  • SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

    BioWorld Science
    Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
  • Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

    BioWorld
    With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
  • Businesswoman pressing dollar sign on touchscreen

    JPM 2026: Year kicks off with biopharma Q4 revenue and guidance

    BioWorld
    It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing